ArticleAmerican journal of translational research2025
Transurethral holmium laser enucleation of prostate shows remarkable efficacy in treating benign prostatic hyperplasia.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Holmium laser enucleation of the prostate improves the renal insufficiency of benign prostatic hyperplasia with hydronephrosis.Translational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effects of transurethral holmium laser enucleation of the prostate (HoLEP) in treating benign prostatic hyperplasia (BPH).
methodsThis retrospective study included 100 BPH patients who visited Foshan Fosun Chancheng Hospital from January 2022 to June 2023. Patients were divided into two groups: 50 treated with transurethral resection of the prostate (control group) and 50 with transurethral HoLEP (observation group). We compared clinical efficacy, surgical parameters, maximum urinary flow rate (Qmax), post-void residual volume (PRV), prostate-specific antigen (PSA), hemoglobin (Hb), interleukin-6 (IL-6), C-reactive protein (CRP), International Prostate Symptom Score (IPSS), quality of life (QOL), and complication rates.
resultsThe observation group showed significantly reduced operative time, blood loss, catheterization duration, and hospitalization compared to the control group (all P<0.05). Postoperatively, Qmax was higher and PRV lower in the observation group (both P<0.05). PSA was lower, and Hb was higher in the observation group than those in the control group (both P<0.05). Both IL-6 and CRP levels increased post-surgery, but were significantly lower in the observation group (both P<0.05). The observation group also had better IPSS and QOL scores and a lower complication rate (16% vs. 56%, all P<0.05).
conclusionHoLEP is an effective treatment for BPH, offering advantages such as reduced surgical time, lower complication rates, improved urodynamics, and better patient outcomes in terms of symptoms and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.